HC Wainwright Reaffirms Buy Rating for Lisata Therapeutics (NASDAQ:LSTA)

HC Wainwright reiterated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a research note released on Thursday morning, Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Lisata Therapeutics Stock Performance

NASDAQ LSTA opened at $2.65 on Thursday. The company has a 50-day simple moving average of $3.02 and a two-hundred day simple moving average of $2.72. Lisata Therapeutics has a 12-month low of $1.95 and a 12-month high of $4.53.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.20. Sell-side analysts expect that Lisata Therapeutics will post -3.08 EPS for the current year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. BML Capital Management LLC grew its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 269,839 shares of the company’s stock after acquiring an additional 26,000 shares during the period. Lisata Therapeutics comprises 0.6% of BML Capital Management LLC’s portfolio, making the stock its 24th largest position. BML Capital Management LLC owned 3.31% of Lisata Therapeutics worth $737,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.